[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338523-105":59,"doc-detail-338523-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","first-line-endocrine-therapy-combined-with-cdk-46-inhibitor-in-disseminated-carcinomatosis-of-bone-marrow-dcbm-luminal-breast-cancer-a-case-report","First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer - a case report","","Metastatic luminal breast cancer with disseminated carcinomatosis of bone marrow (DCBM) carries a life-threatening risk and often requires systemic chemotherapy, yet no official guideline exists for treating DCBM in luminal breast cancer. This case report describes a 36-year-old premenopausal patient with DCBM and visceral crisis who received first-line endocrine therapy combined with a CDK4/6 inhibitor. After intolerance to tamoxifen, treatment was adjusted to letrozole, ribociclib, and leuprorelin. Following six cycles, laboratory blood parameters normalized and symptoms markedly improved, with enhanced quality of life.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-line-endocrine-therapy-combined-with-cdk-46-inhibitor-in-disseminated-carcinomatosis-of-bone-marrow-dcbm-luminal-breast-cancer-a-case-report/338523/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-line-endocrine-therapy-combined-with-cdk-46-inhibitor-in-disseminated-carcinomatosis-of-bone-marrow-dcbm-luminal-breast-cancer-a-case-report/338523.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical condition is highlighted in this case report?","Question",{"text":112,"@type":113},"The report focuses on luminal breast cancer complicated by disseminated carcinomatosis of bone marrow (DCBM), associated with visceral crisis and severe disease risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the patient treated after side effects from initial therapy?",{"text":117,"@type":113},"After intolerance to tamoxifen from first-line treatment, the regimen was adjusted to letrozole plus ribociclib and leuprorelin injection.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were observed after completing treatment cycles?",{"text":121,"@type":113},"After the sixth cycle, blood parameters returned to normal, and the patient showed significant symptom alleviation with improved quality of life.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338523,1790505934,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Pangarsa et al.  \nJournal of Medical Case Reports (2024) 18:591 [https://doi.org/10.1186/s13256-024-04922-4](https://doi.org/10.1186/s13256-024-04922-4)  \nJournal of Medical Case Reports  \n CASE REPORT Open Access  \nFirst-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated  \ncarcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report  \nEko Adhi Pangarsa1,2, Putri Dwi Astuti2, Daniel Rizky1, Kevin Tandarto1*, Budi Setiawan1, Andreas Agung Winarno2, Damai Santosa1 and Catharina Suharti1  \nAbstract  \nBackground Metastatic breast cancer especially in disseminated carcinomatosis of bone marrow (DCBM) poses a life-threatening risk, often requiring systemic chemotherapy. This situation lacks a cure, emphasizing symptom relief and quality of life. The documented occurrence of DCBM is merely 0. 17% in metastatic breast cancer and ranges from 0.6 to 1. 7% in solid tumors. Until now, there is no official medical guideline for treating patients with luminal breast cancer (LBC) who have DCBM. This case report highlights LBC patient with DCBM, treated at diagnosis with first-line therapy combining endocrine therapy (ET) and a CDK4/6 inhibitor.  \nCase presentation A 36-year-old premenopausal female of Javanese ethnicity with advanced de novo luminal breast cancer diagnosed in 2020. The immunohistochemistry showed estrogen receptor (ER)+ (90%), progesterone receptor (PR)+ (20%), human epidermal growth factor receptor 2 (HER-2) negative, and a high Ki-67 staining result at 60% . The patient had visceral crisis, which involved bone marrow infiltration and liver metastasis with preserved liver function. After intolerance of side effects from first line treatment with tamoxifen, the treatment plan was adjusted to letrozole, ribociclib, and leuprorelin injection. After completing the sixth cycle of treatment, blood parameters in the laboratory were found to have returned to normal. The patient’s response to this regimen was remarkable, with significant alleviation of symptoms and improvement in quality of life observed.  \nConclusion Notably, the combined approach of ET and CDK4/6 inhibitor represents a novel intervention in managing DCBM in patients with LBC.  \nKeywords Breast cancer, CDK 4/6 inhibitor, Chemotherapy, Endocrine therapy, Visceral crisis  \n*Correspondence: Kevin Tandarto[tandartok@gmail.com](tandartok@gmail.com)  \n1 Hematology Medical Oncology Division, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital Semarang, Semarang, Indonesia  \n2 . Elisabeth Hospital Semarang, Semarang, Indonesia  \nBackground  \nBreast cancer is the most common type of cancer in women. While metastatic disease, which is often considered incurable, is rarely present at the time of the initial diagnosis, approximately 20% of women with initially treatable breast cancer eventually experience relapses, with 70% of these relapses involving distant metastases [1]. It is important to highlight that while patients with breast cancer frequently experience the spread of cancer to their bone marrow, the occurrence of substantial  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obt","cbCaihQqOTtdQfXa","https://ap.wps.com/l/cbCaihQqOTtdQfXa","pdf",1363460,"English","# Abstract\n## Background\n## Case presentation\n## Conclusion\n## Keywords","[{\"question\":\"What clinical condition is highlighted in this case report?\",\"answer\":\"The report focuses on luminal breast cancer complicated by disseminated carcinomatosis of bone marrow (DCBM), associated with visceral crisis and severe disease risk.\"},{\"question\":\"How was the patient treated after side effects from initial therapy?\",\"answer\":\"After intolerance to tamoxifen from first-line treatment, the regimen was adjusted to letrozole plus ribociclib and leuprorelin injection.\"},{\"question\":\"What outcomes were observed after completing treatment cycles?\",\"answer\":\"After the sixth cycle, blood parameters returned to normal, and the patient showed significant symptom alleviation with improved quality of life.\"}]","First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer - a case report | PDF",1790024033,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3789677f5fa97581af6e7a79c616efd.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc5dd7d713b692f6c3762c67ee1f02ef.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/903916a2e3a5fd1e256bcaed85b31489.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c511e2ad918d9fb20ae333dd66da296.webp",980,1301]